Dataset Information

Stabilization of diverse amyloidogenic antibody light chains by small molecules revealed by hydrogen-deuterium exchange mass spectrometry

ABSTRACT: Antibody light chains can aggregate as amyloid fibrils to cause systemic AL amyloidosis. Amyloid deposition requires unfolding of the light chain from its native state, but the mechanistic details of how this occurs are not fully understood. Inhibiting amyloid formation by stabilizing the precursor light chain proteins against unfolding and proteolysis is a potential therapeutic strategy. Small molecules that bind to the native state of light chains are under development as drug candidates. An important challenge for potential stabilizer drugs is to bind multiple light chains and suppress their dynamics, since every patient has a unique amyloid-forming light chain. Here, we used hydrogen-deuterium exchange measured by mass spectrometry to characterize the binding of six small molecule stabilizers to eleven different λ light chain proteins. Despite structural and dynamic differences among the light chains, the binding of the most efficacious stabilizer molecule led to increased protection from hydrogen exchange, consistent with reduced local and global unfolding. Protection upon binding was most prominent in residues within complementarity determining region 3 and framework region 4 of the light chain variable domains, which undergo major conformational changes upon amyloid formation. Stabilizer binding also reduced the rate at which all light chains were cleaved by protease. These data show how stabilizers can suppress the range of conformational dynamics associated with light chain aggregation, supporting their therapeutic potential.

INSTRUMENT(S):

ORGANISM(S): Homo Sapiens (human)

DISEASE(S): Immunoglobulin Light Chain Amyloidosis

SUBMITTER: Daniele Peterle

LAB HEAD: Thomas Wales

PROVIDER: PXD068745 | Pride | 2026-07-27

REPOSITORIES: Pride

ACCESS DATA

Dataset's files

Source:

			Action	DRS
	Supplemental_data_file.xlsx	Xlsx
	checksum.txt	Txt
	l6_AL_C214S_M83_10m_1.raw.zip	Raw
	l6_AL_C214S_M83_10m_2.raw.zip	Raw
	l6_AL_C214S_M83_10s_1.raw.zip	Raw

Items per page:

1 - 5 of 369

Publications

Small Molecule Stabilization of Diverse Amyloidogenic Immunoglobulin Light Chains Revealed by Hydrogen-Deuterium Exchange Mass Spectrometry.

Peterle Daniele D Yan Nicholas L NL Klimtchuk Elena S ES Srinivasu Bindu Y BY Brusic Vesna V Rhoades Derek D Wales Thomas E TE Gursky Olga O Kelly Jeffery W JW Kelly Jeffery W JW Engen John R JR Morgan Gareth J GJ

Journal of molecular biology 20260629 19

Immunoglobulin light chains, a component of antibodies, can misfold and aggregate to cause systemic AL amyloidosis. Aggregation, including amyloid fibril formation, requires unfolding of the full-length light chain from its native state, and in most cases aberrant proteolysis. Small molecules that bind to the native state of light chains to stabilize them against conformational excursions and proteolysis are under development as drug candidates for AL amyloidosis. Since each patient has a unique ...[more]

PMID: 42372939

Similar Datasets

Project description:Post expression from the host cell, a bio-therapeutic will be subjected to several downstream processing steps prior to final formulation. Analysis of the product under various buffer conditions at each stage is desirable to show that the integrity of the sample is maintained and to monitor any potential product loss. In this study we examine how varying buffer conditions during downstream processing impact the structural integrity of a biopharmaceutical product, with a specific focus on the model IgG1 antibody, mAb4, provided by FUJIFILM Diosynth Biotechnologies. Flexibility, stability, aggregation propensity, and bulk properties were evaluated across the buffers of four sample points, including perfusion media, purification stages, and formulation buffer. Comparisons with Herceptin, an extensively studied IgG1 antibody, were conducted in a mass spectrometry-compatible buffer. Although mAb4 and Herceptin present with similar charge state distributions (CSD) in native mass spectrometry (MS) experiments, they exhibit distinct unfolding patterns during the activated ion mobility-mass spectrometry (aIM-MS) and differential scanning fluorimetry (DSF). The greater structural stability and aggregation onset temperature (Tagg) observed in Herceptin, are primarily attributed to the heavier glycosylation and kappa-class light chains present in Herceptin compared to the lambda-class light chains in mAb4. Hydrogen deuterium exchange mass spectrometry (HDX-MS) revealed that while mAb4 experiences substantial structural changes during purification, characterized by high flexibility, a low melting temperature (Tm), and prevalent repulsive protein-protein interactions, it eventually transitions to a highly compact and stable structure in buffers with higher salt concentrations and during formulation. Notably, in the formulated environment, the third constant domain (CH3) of the heavy chain retains flexibility and is identified as a region of interest for aggregation formation. Here we showcase the integration of MS and orthogonal techniques to attain comprehensive information which can be utilized early in the development stage to aid in decision-making regarding targeted mutations or to guide the design space of bioprocesses and formulation choices.